Literature DB >> 2817595

Prognosis of asthma from childhood to adulthood.

J Gerritsen1, G H Koëter, D S Postma, J P Schouten, K Knol.   

Abstract

The outcome of childhood asthma was studied in 101 adults who came from a group of 119 asthmatic children (85%) 6 to 14 yr of age who had originally been investigated between 1966 and 1969. Changes in respiratory symptoms, spirometry, and airway responsiveness to histamine in childhood and adult life were analyzed. It was found that 43 of the 101 adults (43%) had current symptoms; 29 of the 43 (67%) were receiving maintenance therapy. In the first study, 83 of the 101 children (82%) showed a response on inhalation of histamine (PC10-histamine less than or equal to 16 mg/ml). The number of subjects in the second study who still had a PC10-histamine less than or equal to 16 mg/ml fell to 29, suggesting that airway responsiveness decreases from childhood to adulthood. During the second survey (in adults), 25 of the 43 (59%) subjects with current symptoms and four of the 58 (7%) without respiratory symptoms responded to histamine. Adults with current symptoms had a significantly lower %FEV1 in both childhood and adulthood than did adults without current symptoms; %FEV1 was not different in females and males or in smokers and nonsmokers in either the first or the second survey. The outcome of childhood asthma is primarily predicted by the initial degree of bronchial obstruction (p = 0.041) and airway responsiveness to histamine (p = 0.050), and does not appear to be related to sex, smoking habits, or age of onset of respiratory symptoms.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2817595     DOI: 10.1164/ajrccm/140.5.1325

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  16 in total

1.  Remission of asthma in the middle aged and elderly: report from the Obstructive Lung Disease in Northern Sweden study.

Authors:  E Rönmark; E Jönsson; B Lundbäck
Journal:  Thorax       Date:  1999-07       Impact factor: 9.139

2.  Childhood factors associated with asthma remission after 30 year follow up.

Authors:  J M Vonk; D S Postma; H M Boezen; M H Grol; J P Schouten; G H Koëter; J Gerritsen
Journal:  Thorax       Date:  2004-11       Impact factor: 9.139

Review 3.  Prognostic factors for the outcome of childhood asthma in adolescence.

Authors:  R J Roorda
Journal:  Thorax       Date:  1996-01       Impact factor: 9.139

Review 4.  Epidemiology of asthma and recurrent wheeze in childhood.

Authors:  Anne L Wright
Journal:  Clin Rev Allergy Immunol       Date:  2002-02       Impact factor: 8.667

Review 5.  Asthma: epidemiology, etiology and risk factors.

Authors:  Padmaja Subbarao; Piush J Mandhane; Malcolm R Sears
Journal:  CMAJ       Date:  2009-09-14       Impact factor: 8.262

6.  [Recommendations for implementing bronchial provocation tests with pharmacologic substances. German Society of Pneumology--Scientific "Bronchial Provocation Tests" Study Group].

Authors:  G Klein
Journal:  Med Klin (Munich)       Date:  1997-08-15

7.  Role of infections in the induction and development of asthma: genetic and inflammatory drivers.

Authors:  Qun Wu; Hong Wei Chu
Journal:  Expert Rev Clin Immunol       Date:  2009-01-01       Impact factor: 4.473

8.  Risk factors associated with the presence of irreversible airflow limitation and reduced transfer coefficient in patients with asthma after 26 years of follow up.

Authors:  J M Vonk; H Jongepier; C I M Panhuysen; J P Schouten; E R Bleecker; D S Postma
Journal:  Thorax       Date:  2003-04       Impact factor: 9.139

9.  Asthma and airway hyperresponsiveness among Belgian conscripts, 1978-91.

Authors:  P Dubois; E Degrave; O Vandenplas
Journal:  Thorax       Date:  1998-02       Impact factor: 9.139

10.  Budesonide and terbutaline or terbutaline alone in children with mild asthma: effects on bronchial hyperresponsiveness and diurnal variation in peak flow.

Authors:  H J Waalkens; J Gerritsen; G H Koëter; F H Krouwels; W M van Aalderen; K Knol
Journal:  Thorax       Date:  1991-07       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.